Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

The OncFive: Top Oncology Updates for the Week of 6/1

June 7th 2025

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

T-DXd Plus Pertuzumab Could Disrupt First-Line SOC in HER2+ Metastatic Breast Cancer

June 6th 2025

Tess O’Meara, MD, discusses the implications of data from the DESTINY-Breast09 trial of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

Acalabrutinib-Based Regimens Receive European Approval in Frontline CLL

June 6th 2025

Time-limited therapy with acalabrutinib plus venetoclax with or without obinutuzumab is approved in the European Union for untreated patients with CLL.

FDA Receives NDA for Vepdegestrant in ESR1-Mutated, ER+/HER2– Metastatic Breast Cancer

June 6th 2025

The FDA received an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer with an ESR1 mutation.

Dr Rugo on Research Needed to Clarify the Role of T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 6th 2025

Hope Rugo, MD, discusses the application of findings from the DESTINY-Breast09 trial of T-DXd plus pertuzumab in HER2-positive breast cancer.

Dr Rugo on Ongoing ADC Investigations Set to Shift Practice in HER2+ Breast Cancer

June 6th 2025

Hope Rugo, MD, discusses the evolving use of antibody-drug conjugates in HER2-positive breast cancer.

Pirtobrutinib Adds Effective Option to CLL Treatment Landscape, Underscoring Treatment Selection Considerations

June 6th 2025

Nitin Jain, MD, discusses the role pirtobrutinib has played in the chronic lymphocytic leukemia treatment paradigm.

Experts Underscore the Top Abstracts to Watch at the 2025 EHA Congress

June 6th 2025

Experts highlight key abstracts to watch for at the 2025 EHA Congress.

RP1 Yields Responses in Deep/Visceral Lesions and Across Injected/Non-Injected Lesions in Advanced PD-1–Refractory Melanoma

June 6th 2025

RP1/nivolumab generated responses in deep/visceral lesions and in non-injected lesions in advanced PD-1–refractory melanoma.

Generic Eltrombopag Expands Access and Flexibility in ITP and Severe Aplastic Anemia

June 5th 2025

Kanwarpal S. Kahlon, MD, discusses the implications of the availability of generic eltrombopag for immune thrombocytopenia and severe aplastic anemia.

Casdozokitug Plus Atezolizumab/Bevacizumab Yields Antitumor Activity in Unresectable, Advanced HCC

June 5th 2025

Daneng Li, MD, discusses the efficacy and safety findings of a casdozokitug-based regimen in unresectable, advanced HCC.

IMA203 Demonstrates Early Promise in PD-1–Refractory Metastatic Melanoma

June 5th 2025

IMA203 was well tolerated and elicited durable responses in patients with advanced melanoma.

Dr Saad on the FDA Approval of Darolutamide in mCSPC

June 4th 2025

Fred Saad, MD, discusses the FDA’s approval of darolutamide without chemotherapy for metastatic castration-sensitive prostate cancer

BNT327/PM8002 Plus Chemo Is Active in Unresectable Pleural and Peritoneal Mesothelioma

June 4th 2025

Frontline BNT327/PM8002 plus chemotherapy was effective and safe in patients with unresectable pleural and peritoneal mesothelioma.

Annamycin Drives Clinical Benefit in Soft Tissue Sarcoma Lung Metastases

June 4th 2025

Annamycin yielded a 59.4% CBR and a median OS of 13.5 months in soft tissue sarcoma lung metastases.

Iopofosine I 131 Earns FDA Breakthrough Designation for R/R Waldenström Macroglobulinemia

June 4th 2025

The FDA granted breakthrough therapy designation to iopofosine I 131 for relapsed/refractory Waldenström macroglobulinemia.

Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer

June 3rd 2025

An exploratory analysis showed a reduction in the risk of progression in locally advanced cervical cancer with undetectable ctDNA levels after treatment.

Perioperative IMNN-001 Plus Chemo Yields Improved Survival Trends in Newly Diagnosed Advanced Epithelial Ovarian Cancer

June 3rd 2025

Perioperative IMNN-001 plus chemotherapy generated numerical survival improvements in newly diagnosed epithelial ovarian cancer.

Brentuximab Vedotin Plus Chemo Wins EU Approval for Newly Diagnosed, Stage IIB-IV Hodgkin Lymphoma

June 3rd 2025

Brentuximab vedotin plus ECADD chemotherapy has been approved in Europe for adult patients with newly diagnosed, stage IIB to IV Hodgkin lymphoma.

NCCN Adds 2 Tests to CRC Screening Guidelines

June 3rd 2025

The NCCN has added the Shield blood test and the ColoSense test to its colorectal cancer screening guidelines.